PMC:7074432 / 1755-2391
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
81 | 0-13 | Gene | denotes | Neuraminidase | Gene:4758 |
96 | 25-38 | Gene | denotes | Neuraminidase | Gene:4758 |
97 | 122-130 | Species | denotes | MERS-CoV | Tax:1335626 |
98 | 179-187 | Species | denotes | patients | Tax:9606 |
99 | 221-229 | Species | denotes | patients | Tax:9606 |
100 | 243-258 | Species | denotes | influenza virus | Tax:11309 |
101 | 379-387 | Species | denotes | MERS-CoV | Tax:1335626 |
102 | 448-456 | Species | denotes | MERS-CoV | Tax:1335626 |
103 | 509-518 | Species | denotes | 2019-nCoV | Tax:2697049 |
104 | 85-94 | Species | denotes | influenza | Tax:11309 |
105 | 197-208 | Chemical | denotes | oseltamivir | MESH:D053139 |
106 | 291-302 | Chemical | denotes | oseltamivir | MESH:D053139 |
107 | 339-350 | Chemical | denotes | oseltamivir | MESH:D053139 |
108 | 433-444 | Chemical | denotes | oseltamivir | MESH:D053139 |
109 | 462-473 | Chemical | denotes | Oseltamivir | MESH:D053139 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T108 | 14-24 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T107 | 39-49 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T106 | 122-130 | SP_9 | denotes | MERS-CoV |
T105 | 197-208 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T104 | 243-252 | NCBITaxon:7719 | denotes | influenza |
T103 | 253-258 | NCBITaxon:10239 | denotes | virus |
T102 | 291-302 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T101 | 339-350 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T100 | 379-387 | SP_9 | denotes | MERS-CoV |
T99 | 433-444 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T98 | 448-456 | SP_9 | denotes | MERS-CoV |
T97 | 462-473 | CHEBI:7798;CHEBI:7798 | denotes | Oseltamivir |
T96 | 509-518 | SP_7 | denotes | 2019-nCoV |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T13 | 85-94 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T14 | 243-252 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 102-103 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T9 | 165-166 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 176-178 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 35 |
T11 | 253-258 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T12 | 269-271 | http://purl.obolibrary.org/obo/CLO_0001407 | denotes | 52 |
T13 | 458-460 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T14 | 0-24 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
T15 | 14-24 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T16 | 25-49 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
T17 | 39-49 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T18 | 197-208 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T19 | 291-302 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T20 | 339-350 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T21 | 433-444 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T22 | 462-473 | Chemical | denotes | Oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T23 | 611-616 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 0-24 | Sentence | denotes | Neuraminidase inhibitors |
T15 | 25-217 | Sentence | denotes | Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). |
T16 | 218-636 | Sentence | denotes | In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12] |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32201439-30012113-47219407 | 395-397 | 30012113 | denotes | 10 |
32201439-30882305-47219408 | 458-460 | 30882305 | denotes | 11 |
32201439-31986264-47219409 | 633-635 | 31986264 | denotes | 12 |
T19064 | 395-397 | 30012113 | denotes | 10 |
T33497 | 458-460 | 30882305 | denotes | 11 |
T42850 | 633-635 | 31986264 | denotes | 12 |